Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy

• Main Authors: Md. Prova Zaman Emon, Rajesh Das, Nuruna Lovely Nishuty, M. M. A. Shalahuddin Qusar, Mohiuddin Ahmed Bhuiyan, Md. Rabiul Islam
• Format: Article
• Language: English
• Published: BMC 2020-02-01
• Series: BMC Research Notes
• Subjects: Serum BDNF; Major depressive disorder; MDD; Case–control study; Bangladesh
• Online Access: http://link.springer.com/article/10.1186/s13104-020-04952-3

Abstract Objective We do not have any consistent markers for major depressive disorder (MDD) though various biological factors are involved in the pathophysiology. We aimed to evaluate the serum brain-derived neurotrophic factor (BDNF) levels in MDD patients with or without antidepressant therapy compared to healthy controls (HCs). Results We assessed serum BDNF levels among three groups: drug-naïve MDD patients (n = 41), drug-treated MDD patients (n = 44), and age-and sex-matched HCs (n = 82). Serum BDNF levels were measured by enzyme-linked immunosorbent assay (ELISA) kit. Serum levels of BDNF were detected significantly lower in drug-naïve MDD patients compared to HCs. No significant alterations of serum BDNF levels between drug-treated patients and HCs were identified. Significant negative correlations between serum BDNF levels and Hamilton depression rating (Ham-D) scores were observed in both drug-naïve and drug-treated MDD patients. Receiver operating characteristic (ROC) analysis showed good diagnostic value for serum BDNF levels in drug-naïve MDD patients with the area under the curve at 0.821. The present study suggests that low serum BDNF levels may be involved in the pathophysiology of MDD. The reduced serum BDNF levels might be used as an early risk assessment marker for major depression.